NESS ZIONA, Israel, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today ...
Psilocybin trials show poorer control group outcomes compared to SSRIs and esketamine, potentially inflating perceived efficacy due to expectancy bias and functional unblinding. Control group response ...
Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today provided an update on enrollment from its November report with an increase to 78% of the target number of subjects for the ...
A recent study published in Brain Communications discusses critical questions regarding the evaluation of anti-amyloid immunotherapies for the treatment of Alzheimer’s disease. Study: Key questions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback